Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | CC-92480: a novel CELMoD, in R/R myeloma

Paul Richardson • 24 Jun 2020
EHA 2020
Multiple Myeloma Dexamethasone Iberdomide Lenalidomide Mezigdomide Pomalidomide

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the first-in-human Phase I study of the novel CELMoD agent mezigdomide (CC-92480), a cereblon E3 ligase modulator, for relapsed/refractory multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paul Richardson

Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
4:13
Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
Paul Richardson • 7 Dec 2025
Belantamab mafodotin combined with pomalidomide and dexamethasone in RRMM: HRQoL in DREAMM-8
4:20
Belantamab mafodotin combined with pomalidomide and dexamethasone in RRMM: HRQoL in DREAMM-8
Paul Richardson • 7 Dec 2025
STOMP: selinexor, mezigdomide, & dexamethasone in patients with RRMM
3:33
STOMP: selinexor, mezigdomide, & dexamethasone in patients with RRMM
Paul Richardson • 7 Dec 2025
The treatment landscape for patients with multiple myeloma at first relapse
3:32
The treatment landscape for patients with multiple myeloma at first relapse
Paul Richardson • 19 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Paul Richardson • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Paul Richardson • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Paul Richardson • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Paul Richardson • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals